Treatment with treprostinil, a medicine that relaxes blood vessels, led to significant and sustained improvements in children with pulmonary hypertension (PH) caused by different lung conditions, according to a retrospective analysis. Findings from the analysis were detailed in the study, “Treprostinil Is Associated With Early and Sustained Improvement…
A team of scientists in China identified four genes that may serve as potential treatment targets for idiopathic pulmonary arterial hypertension (PAH). “This study combined [computer-based genetic sequencing] analyses with experimental validation [in cell and animal models] to identify COL1A1, MYL9, COL1A2, and TPM2 as potential key driver genes…
Scientists in China have developed a phosphodiesterase-5 (PDE5) inhibitor for pulmonary arterial hypertension (PAH) that reduced disease severity in a rat model of PAH. The scientists detailed the development and testing of the treatment, CPD1, in a study that also shed light on the molecular mechanisms through which the…
Advocates worldwide are gearing up for World Pulmonary Hypertension Day on May 5, focusing this year on the critical role of clinical research. Led by PHA Europe, the annual event seeks to raise awareness and improve the lives of those living with pulmonary hypertension (PH), a condition…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
